In the Zone: smart biomarker assays

Biomarkers can belong to many diverse classes of molecules, such as lipids, steroids, sugars, even peptides and proteins. Most biomarkers are amenable to LC-MS/MS, however, very polar biomarkers that might not be easily analyzed via LC-MS/MS can be analyzed via derivatization followed by GC-MS/MS. In addition, peptide and protein biomarkers may require digestion before they can be analyzed and depending upon sensitivity needs, an immunocapture step may be required.

In this In the Zone feature, we will explore what you need to consider when developing smart assays and what the future will be for the field following the COVID-19 pandemic.

INFOGRAPHIC

Infographic: Considerations for developing a smart biomarker assay – In this infographic, we will explore what to take into account when developing a smart biomarker assay and what type of guidance to follow depending on the endpoint.

INTERVIEW

The significance of smart biomarkers: an interview with Sharon DeChenne – In this interview, we discuss what a smart biomarker is and what the benefits and challenges are when developing these assays.

RESOURCES

Critical reagent screening and characterization: benefits and approaches for protein biomarker assays by hybrid LC–MS

A multilaboratory validation study of LC/MS biomarker assays for three lysophosphatidylcholines

Exploratory biomarker assays: key assay parameters to evaluate in the face of evolving biomarker context-of-use

In association with:

[Video edit by Sandra Kongo-Bacary]